Arie Levine
YOU?
Author Swipe
View article: Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed‐up Study)
Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed‐up Study) Open
Objectives: Escalation of the ustekinumab (UST) maintenance dosage was effective in adults with Crohn disease (CD), but no data are available for children. We evaluated the effectiveness and safety of dose escalation of UST in pediatric CD…
View article: P711 Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment
P711 Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatment Open
Background Early relapse in children with Crohn’s Disease (CD) after reaching remission is associated with a more severe disease course that significantly impairs quality of life. We have previously shown that a Bayesian approach predicted…
View article: P458 Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn’s disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHAN
P458 Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn’s disease (the SPEED-UP study) - A multi-center study from the paediatric IBD Porto group of ESPGHAN Open
Background Ustekinumab (UST) is an effective therapy for induction and maintenance of remission in Crohn’s disease (CD). Intensification of UST maintenance dosage has shown effectiveness in some adult patients, but no similar data are avai…
View article: A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study
A Novel UC Exclusion Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A Prospective Open-Label Pilot Study Open
Background: As the microbiome plays an important role in instigating inflammation in ulcerative colitis (UC), strategies targeting the microbiome may offer an alternative therapeutic approach. The goal of the pilot trial was to evaluate th…
View article: The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry
The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry Open
Background and Aims Guidelines regarding thromboprophylaxis for venous thromboembolisms [VTEs] in children with inflammatory bowel disease [IBD] are based on limited paediatric evidence. We aimed to prospectively assess the incidence of VT…
View article: Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial
Use of Faecal Transplantation with a Novel Diet for Mild to Moderate Active Ulcerative Colitis: The CRAFT UC Randomised Controlled Trial Open
Background We evaluated whether integration of novel diets for donors and patients, in addition to faecal transplantation [FT], could increase FT remission rate in refractory ulcerative colitis [UC]. Methods This was a blinded, randomised,…
View article: OP32 Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patients
OP32 Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn’s Disease patients Open
Background Early relapse in paediatric Crohn’s Disease (CD) is associated with severe disease course that heavily impairs quality of life. Changes in gut microbiome composition have been linked to active CD and disease course. This has led…
View article: P492 The UC Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A prospective open label pilot study
P492 The UC Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A prospective open label pilot study Open
Background Strategies that target the microbiome may offer an alternative therapeutic approach for Ulcerative Colitis (UC). The goal of the pilot trial was to evaluate the efficacy of a novel microbe-directed UC diet (UCD) for clinical rem…
View article: MODERATE TO SEVERE ENDOSCOPIC INFLAMMATION IS FREQUENT AFTER ACHIEVING CLINICAL REMISSION IN PEDIATRIC ULCERATIVE COLITIS
MODERATE TO SEVERE ENDOSCOPIC INFLAMMATION IS FREQUENT AFTER ACHIEVING CLINICAL REMISSION IN PEDIATRIC ULCERATIVE COLITIS Open
Background Pediatric ulcerative colitis (UC) is characterized by low sustained remission rates and frequent extension of disease even if clinical remission is obtained with therapy. Moderate to severe endoscopic activity is a risk factor f…
View article: Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment
Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment Open
Background The REDUCE-RISK trial was set up to compare the effectiveness of weekly subcutaneously administered methotrexate with daily oral azathioprine or 6-mercaptopurine in low-risk Crohn disease (CD) or subcutaneously administered adal…
View article: The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update Open
Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn’s disease [CD]. Methods We formed 10 working groups and formulated 17 PICO-structured clinical questions…
View article: International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study
International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study Open
Introduction Patients with paediatric-onset inflammatory bowel disease (PIBD) may develop a complicated disease course, including growth failure, bowel resection at young age and treatment-related adverse events, all of which can have sign…
View article: Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course
Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course Open
Introduction Immunomodulators such as thiopurines (azathioprine (AZA)/6-mercaptopurine (6MP)), methotrexate (MTX) and biologics such as adalimumab (ADA) are well established for maintenance of remission within paediatric Crohn’s disease (C…
View article: A Case-Based Approach to New Directions in Dietary Therapy of Crohn’s Disease: Food for Thought
A Case-Based Approach to New Directions in Dietary Therapy of Crohn’s Disease: Food for Thought Open
Recent evidence has demonstrated that Crohn’s disease may have its roots in dysbiosis of the microbiome and other environmental factors. One of the strongest risk factors linked to immune activation appears to be diet. Exclusion diets have…
View article: OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease
OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease Open
Background Dietary therapy with the Crohn’s disease Exclusion Diet (CDED) or Exclusive Enteral Nutrition (EEN) induces remission, reduces inflammation and is associated with compositional changes in the microbiome. We performed metagenome …
View article: Antibiotic Cocktail for Pediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized Controlled Trial
Antibiotic Cocktail for Pediatric Acute Severe Colitis and the Microbiome: The PRASCO Randomized Controlled Trial Open
Background Alterations in the microbiome have been postulated to drive inflammation in IBD. In this pilot randomized controlled trial, we evaluated the effectiveness of quadruple antibiotic cocktail in addition to intravenous-corticosteroi…
View article: Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn’s Disease Cohort
Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn’s Disease Cohort Open
Background The beneficial effects of antibiotics in Crohn’s disease (CD) depend in part on the gut microbiota but are inadequately understood. We investigated the impact of metronidazole (MET) and metronidazole plus azithromycin (MET+AZ) o…
View article: Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment (Preprint)
Identifying Health Economic Considerations to Include in the Research Protocol of a Randomized Controlled Trial (the REDUCE-RISK Trial): Systematic Literature Review and Assessment (Preprint) Open
BACKGROUND The REDUCE-RISK trial was set up to compare the effectiveness of weekly subcutaneously administered methotrexate with daily oral azathioprine or 6-mercaptopurine in low-risk Crohn disease (CD) or subcutaneously administered ada…
View article: Initial Development and Validation of a Transition Readiness Scale for Adolescents with Inflammatory Bowel Disease
Initial Development and Validation of a Transition Readiness Scale for Adolescents with Inflammatory Bowel Disease Open
Background and Aims . To date, there are no validated measures in IBD to assess the level of preparedness for transition into adult health care. The purpose of this study was to develop and assess the reliability and validity of a “Transit…
View article: Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn’s Disease: Results From the Porto Group GROWTH Study
Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn’s Disease: Results From the Porto Group GROWTH Study Open
Introduction The ability to predict risk for poor outcomes in Crohn’s disease [CD] would enable early treatment intensification. We aimed to identify children with CD with complications at baseline and throughout the study period who are a…
View article: OP05 Crohn’s disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in mild-to-moderate active paediatric Crohn’s disease: a prospective randomised controlled trial
OP05 Crohn’s disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in mild-to-moderate active paediatric Crohn’s disease: a prospective randomised controlled trial Open
Exclusive enteral nutrition (EEN; consumption of a liquid formula without other food for 6–8 weeks) is the recommended first-line therapy for induction of remission in children with mild-to-moderate Crohn's disease (CD). The CD exclusion d…
View article: P572 Half of children with acute severe colitis have predominant single faecal bacterial species, mostly Escherichia coli: Microbiome results from the PRASCO trial
P572 Half of children with acute severe colitis have predominant single faecal bacterial species, mostly Escherichia coli: Microbiome results from the PRASCO trial Open
Acute severe ulcerative colitis (ASC) is one of the few medical emergencies of gastroenterology. We previously reported the clinical results of the PRASCO randomised controlled trial in which oral antibiotics (AB) improved disease activity…
View article: P689 The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease
P689 The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease Open
Childhood is a critical time for accrual of bone density, which peaks at age 18–20 years. Both the inflammatory burden of CD and corticosteroid therapy have a negative effect on bone density, hence exclusive enteral nutrition (EEN) is the …
View article: P346 Small bowel permeability improves with nutritional therapy in mild-to-moderate active paediatric Crohn’s disease
P346 Small bowel permeability improves with nutritional therapy in mild-to-moderate active paediatric Crohn’s disease Open
Intestinal permeability (IP) is increased in Crohn’s disease (CD) patients and their first degree relatives. The causes of barrier disruption remain unclear but likely relate to inflammation with possible effects of nutrients and microbes.…